The clinical trial is part of its strategy to conduct human clinical trials to test the efficacy of the Deep TMS system.
Brainsway Ltd. (TASE:BRIN) yesterday announced that it obtained permission from the Hadassah Medical Organization's ethics committee to conduct a clinical trial on children of the company's non-invasive Deep TMS (transcranial magnetic stimulate) devices for the treatment of autism. The lead researchers are Dr. Michal Begin and Dr. Moshe Isserles.
The Ministry of Health still has to approve the clinical trial.
Brainsway said that the clinical trial is part of its strategy to conduct human clinical trials to test the efficacy of the Deep TMS system for the treatment of a range of neurological disorders in collaboration with leading hospitals in the world.
Brainsway's share price was unchanged at NIS 27.14 by midday today, giving a market cap of NIS 321 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 22, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011